Objective
early-stage ERBB2/HER2-positive, breast cancer
BREAST CANCER
To examine the prognostic ability of TILs and immune-related gene expression signatures, alone and in combination, to predict pCR and EFS in patients with early-stage ERBB2/HER2-positive breast cancer treated in 2 clinical trials.